secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2024-06-10T23:59:59+00:00
Accession:  0001517022-24-000057
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Akebia Therapeutics shareholders reject proposal to increase share reserve by 9.8M shares
--------------------------------------------------------------------------------

- Three Class I directors elected: Ronald E. Frieson, Steven C. Gilman, Ph.D., Cynthia Smith.
- Proposal to increase 2023 Stock Incentive Plan by 9.8M shares failed (52.8M against vs 45.2M for).
- Advisory say-on-pay compensation approved narrowly (48.9M for, 47.4M against).
- Ratification of Ernst & Young as independent auditor for FY 2024 approved (120.2M for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000057/0001517022-24-000057-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000057/akba-20241006cfo.htm
  HTML page:      https://secwatch.observer/filing/0001517022-24-000057

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer